Fränzi Weibel

Title: Fränzi Weibel: Innovator in Modified IL-2 Polypeptides

Introduction

Fränzi Weibel is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of modified IL-2 polypeptides. His work focuses on innovative treatments for diseases, including cancer.

Latest Patents

Fränzi Weibel holds a patent for "Modified IL-2 polypeptides and uses thereof." This patent describes modified IL-2 polypeptides, compositions that include these polypeptides, and methods for their production and application. The invention emphasizes the use of these modified polypeptides in treating diseases, particularly cancer. Notably, the disclosed IL-2 polypeptides demonstrate preferential binding to the IL-2 receptor βγ complex over the IL-2 receptor αβγ complex. Additionally, the molecular weight distribution of these modified IL-2 polypeptides is monodispersed, enhancing their therapeutic potential.

Career Highlights

Fränzi Weibel is associated with Bright Peak Therapeutics AG, where he continues to advance his research and development efforts. His innovative approach to biotechnology has positioned him as a key figure in the industry.

Collaborations

Fränzi Weibel has collaborated with notable professionals in his field, including Vijaya Raghavan Pattabiraman and Roberto Iacone. These collaborations have further enriched his research and contributed to the advancement of therapeutic solutions.

Conclusion

Fränzi Weibel's work in modified IL-2 polypeptides represents a significant advancement in the treatment of diseases, particularly cancer. His innovative contributions continue to shape the future of biotechnology and therapeutic development.